Cancer - breast news and cancer - breast widget

Audrey Birt, Breakthrough breast cancer's Director for Scotland says: "Breakthrough Breast cancer welcomes the publication today of Better Cancer Care. It's now essential that clear plans are put in place to ensure the recommendations in this report are implemented as soon as possible. In order to translate this into real benefits it is also essential that patients are involved in the development of cancer services.

Title: Statins Lower Risk of Clots in cancer PatientsCategory: health newscreated: 10/28/2008 2:00:00 amlast Editorial review: 10/28/2008

Dawn Martinez's mother battled ovarian cancer for eight years. Her aunt, cousin and great-aunts all had breast cancer. So when her doctor suggested she undergo genetic testing to see if she, too, was at risk, she didn't hesitate. The test was positive -- Martinez had indeed inherited a gene mutation that put her at a more than 80 percent chance of developing breast cancer, and at least a 45 percent chance of getting ovarian cancer. So, at age 35 and still cancer free, Martinez, who lives in Mission, made a drastic decision. She had a hysterectomy, and two months later, a double mastectomy, followed by breast reconstructive surgery. That was more than a year ago, and Martinez, who is married with four children, doesn't regret her ch...

KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma. Craig Dees, CEO of Provectus, noted, "We are very pleased with the results of this Phase 1 clinical trial, a classic ascending dose study. Its goals were to determine the safety of the treatment and the appropriate dosage. We have also wanted to show that PV-10 has multi-indication potential. We succeeded in meeting these goals. We are now in a position for a Phase 2 study in recurrent breast carcinoma with our lead oncology drug product candidate PV-10." Dees continued...